Baxter International
About: Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Employees: 38,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
271% more call options, than puts
Call options by funds: $113M | Put options by funds: $30.6M
1.47% more ownership
Funds ownership: 94.83% [Q1] → 96.31% (+1.47%) [Q2]
9% less funds holding
Funds holding: 826 [Q1] → 751 (-75) [Q2]
10% less capital invested
Capital invested by funds: $16.7B [Q1] → $15B (-$1.67B) [Q2]
11% less repeat investments, than reductions
Existing positions increased: 256 | Existing positions reduced: 289
29% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 5 (-2) [Q2]
44% less first-time investments, than exits
New positions opened: 69 | Existing positions closed: 124
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Barclays Matt Miksic | 47%upside $36 | Overweight Maintained | 4 Aug 2025 |
Stifel Rick Wise | 2%upside $25 | Hold Downgraded | 4 Aug 2025 |
UBS Danielle Antalffy | 2%downside $24 | Neutral Maintained | 4 Aug 2025 |
Wells Fargo Larry Biegelsen | 2%downside $24 | Equal-Weight Maintained | 1 Aug 2025 |
Morgan Stanley Patrick Wood | 10%upside $27 | Underweight Maintained | 15 Jul 2025 |
Financial journalist opinion
Based on 14 articles about BAX published over the past 30 days
